Breaks Categories: News

TuesdayAug 01, 2023 10:53 am

BioMedNewsBreaks – Ocean Biomedical Inc. (NASDAQ: OCEA) Shares Promising Results on World Lung Cancer Day

On World Lung Cancer Day, Ocean Biomedical (NASDAQ: OCEA) shared details of its multipronged lung cancer program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. According to the announcement, Dr. Elias and his team have revealed that Chitinase 3-like-1 (“CHi3L1”) is a master regulator that inhibits antitumor immune responses. Ocean Biomedical’s lung cancer program is advancing several approaches to reversing immune system suppression caused by CHi3L1 alone and in combination with other immunotherapy pathways. The programs suppress primary and metastatic tumor growth in numerous animal models and hold potential use in multiple forms of visceral cancers.…

Continue Reading

ThursdayJul 27, 2023 12:39 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Abstract Selected for Poster Presentation at 2023 SNO/ASCO CNS Cancer Conference

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its abstract was selected for in-person poster presentation at the 2023 SNO/ASCO CNS Cancer Conference taking place in San Francisco from Aug. 10-12, 2023. Sandra Silberman, MD, PhD, chief medical officer of CNS Pharmaceuticals, will present the abstract titled, “A randomized, controlled trial of Berubicin, a topoisomerase II poison that appears to cross the blood-brain barrier (‘BBB’), after first-line therapy for glioblastoma multiforme (‘GBM’): Preliminary Results.” Dr. Silberman’s…

Continue Reading

ThursdayJul 27, 2023 11:59 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q2 2023 Results Call, Webcast

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced that it will hold a conference call to discuss its results for the second quarter ended June 30, 2023. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno and CFO Richard Brounstein will host the call at 4:30 p.m. Eastern Time on Thursday, Aug. 10, 2023. Topics will include a review of recent announcements, ongoing initiatives and key 2023 milestones, followed by a question-and-answer period. Interested parties can visit https://ibn.fm/fiRyL to register for…

Continue Reading

WednesdayJul 26, 2023 12:51 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Experienced Physician, Researcher to Board of Directors

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, has announced a new member of its board of directors: Michael R. Jaff, DO. This appointment brings the number of board members to eight. A renowned vascular physician and researcher, Jaff has an impressive background in the clinical and industry space. He will add “a unique and extremely valuable perspective that is crucial for HeartBeam as we progress toward our initial clearances and the commercial availability of our technology,” the announcement stated. Currently the chief…

Continue Reading

TuesdayJul 25, 2023 3:16 pm

BioMedNewsBreaks – HippoFi Inc. (ORHB) Announces Launch of PURmarrow 360, Strategic Partnership for Near-Term Commercialization of New Technology

HippoFi (OTC: ORHB) is a leading health care technology company and authority in spinal biologics, focused on the development and distribution of innovative biotech products. The company today announced that, over the last six months, while under a confidential letter of intent (“LOI”) in a strategic partnership, it has designed and formulated a strategic launch of the PURmarrow 360 bone marrow aspirate (“BMA”) device throughout the United States. The product is a natural extension to HippoFi’s robust product line, allowing surgeons to selectively capture highly desired cells from a patient’s own BMA during surgery. The rich marrow enhances the effectiveness…

Continue Reading

TuesdayJul 25, 2023 3:09 pm

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW), Partners Launch Proven Breakthrough Hair-Booster System in India

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, in partnership with its regional distributors, has launched Cosmofix MinoxiBoost in India. JUPW’s distributors are Sanpellegrino Cosmetics Pvt Ltd and Cosmofix Technovation Pvt Ltd, which have exclusive distribution rights to the company’s patented hair-growth technology in 31 countries in Asia and the Middle East including India, the Philippines, Malaysia, Kuwait, Morocco and Saudi Arabia. According to the announcement, MinoxiBoost has been clinically proven to increase essential hair enzymes and is designed to be integrated into the daily minoxidil routine of people seeking increased hair growth. The announcement also noted that based on the distribution agreement,…

Continue Reading

FridayJul 21, 2023 11:26 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Water Tower Research Fireside Chat Series

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that Jerry Griffin, VP of Sales and Marketing for InMed’s subsidiary BayMedica LLC, a leading supplier of bioidentical rare cannabinoids to the health and wellness (“H&W”) market, will be participating in a fireside chat with Water Tower Research on July 25, 2023, at 2:00 p.m. ET. The event is open for all investors with topics that include an overview of BayMedica, its competitive environment and upcoming catalysts, as well as the market dynamics of rare…

Continue Reading

ThursdayJul 20, 2023 1:33 pm

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Results from ‘Groundbreaking’ Sponsored Study Measuring Psychedelic Effects

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on the release of study findings. Cybin sponsored the study, which was conducted by Kernel, a leader in noninvasive neuroimaging. Titled “Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS,” the study was published in “Scientific Reports from the Nature Portfolio of Journals” and evaluated the ability of Kernel’s Flow1 system to capture and analyze brain changes resulting from the administration of a psychoactive substance. According to the announcement, the single-blind, placebo-controlled…

Continue Reading

ThursdayJul 20, 2023 12:37 pm

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Board Appointments of GBB Drink Lab Founder and President and Beverage Industry Veteran

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced the appointment of John Gulyas to its board of directors and Rich Pascucci to its advisory board. Both Gulyas and Pascucci are formerly from GBB Drink Lab, creator of Safety Shot, the world’s first rapid blood alcohol detoxification drink recently acquired by Jupiter Wellness. “We are very pleased to have more of the stellar GBB Drink Lab team join Jupiter. John’s track record as a serial entrepreneur and innovator speaks for itself. With his passion, drive and know-how in moving Safety Shot from concept to market…

Continue Reading

ThursdayJul 20, 2023 12:01 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on BayMedica Rare Cannabinoid Business

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today provided a commercial and manufacturing update on its subsidiary BayMedica LLC, a leading supplier of bioidentical rare cannabinoids to the health and wellness (“H&W”) market. Among the highlights, the company reported a 123% quarter-over-quarter increase in revenues. “We are very encouraged to see another strong quarter with (unaudited) revenues in excess of $2.3M, representing our third consecutive quarter with significant revenue growth,” said Eric A. Adams, InMed’s president and CEO. “As demand for minor cannabinoids continues to increase, we…

Continue Reading